Ligand Pharmaceuticals Incorporated 13D and 13G filings for Pelthos Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-10 4:42 pm Purchase | 2025-11-06 | 13D | Pelthos Therapeutics Inc. PTHS | LIGAND PHARMACEUTICALS INC LGND | 5,189,177 49.900% | 261,309 (+5.30%) | Filing |
| 2025-07-03 4:05 pm Purchase | 2025-07-01 | 13D | Pelthos Therapeutics Inc. PTHS | LIGAND PHARMACEUTICALS INC LGND | 4,927,868 49.900% | 4,927,868 (New Position) | Filing |